Constantinos G Hadjipanayis MD PhD Appointed Chair of the Department of Neurosurgery at Mount Sinai Beth Israel

New York
 – October 6, 2015 /Press Release/  –– 

Renowned surgical neuro-oncologist Constantinos (Costas) G. Hadjipanayis has been named Professor and Chair of the Department of Neurosurgery at Mount Sinai Beth Israel.  He has also been appointed as Director of Neurosurgical Oncology for the Mount Sinai Health System and Director of the Brain Tumor Nanotechnology Laboratory in the Tisch Cancer Institute.

“I am delighted to welcome this rising star to the leadership team at Mount Sinai Beth Israel, where he will oversee growth and development of neurosurgery at this important hospital” says Joshua Bederson, MD, Chairman of Neurosurgery for the Mount Sinai Health System. “Costas brings passion, innovation, and extraordinary talent to our superb team of brain tumor surgeons.”

Both as a neurosurgeon and an NIH-funded scientist, Dr. Hadjipanayis is recognized as a neuro-oncology pioneer, leading cooperative group- and industry-sponsored clinical trials for patients with malignant brain tumors.  He was the first in the US to perform fluorescence-guided surgery for malignant gliomas with the use of a 5-aminolevulinic acid (5-ALA) drug called Gliolan, which can light up otherwise invisible brain tumors in the operating room.  His laboratory developed a unique trial for brain tumors using magnetic nanoparticle therapeutic agents that can target brain tumor cells and can also be seen by MRI.

Dr. Hadjipanayis’ interests include surgery and experimental therapeutics for malignant brain tumors, neuro-endoscopy for pituitary tumors and especially colloid cysts, for which his published experience is one of the largest reported. In addition, he performs microsurgery and radiosurgery for tumors of the skull base and spinal cord.

Dr. Hadjipanayis received his medical degree from Jefferson Medical College in Philadelphia.  He completed his internship and residency in neurosurgery at the University of Pittsburgh School of Medicine, simultaneously obtaining his PhD in the Department of Molecular Genetics and Biochemistry.  He pursued further advanced training in awake craniotomy techniques and intraoperative cortical/subcortical mapping at the University of California San Francisco (UCSF).

Prior to joining Mount Sinai, Dr. Hadjipanayis was an Associate professor in the Department of Neurosurgery at Emory University School of Medicine, Chief of Neurosurgery at Emory University Hospital Midtown, and Director of the Winship Brain Tumor Center of Emory. He was also the President of the Georgia Neurosurgical Society and the Southeastern Brain Tumor Foundation.

About The Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—.from community-based facilities to tertiary and quaternary care.

The System includes approximately 6,100 primary and specialty care physicians; 12 minority-owned free-standing ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. Seven departments at The Mount Sinai Hospital and one at the New York Eye and Ear Infirmary (NYEE) ranked nationally in the top 25 in the 2015-2016 “Best Hospitals” issue of U.S. News & World Report. Mount Sinai’s Kravis Children’s Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report.     

For more information, visit or find Mount Sinai on Facebook, Twitter and YouTube.

# # #